Monoclonal antibody targeting CTLA-4, administered as intravenous infusion in immunotherapy protocols for unresectable malignant mesothelioma and other solid tumors. Acquired by cancer treatment hospitals and research institutions from biopharmaceutical producers and oncology distributors.